Epigenomics Ag Stock Today

EPGNF Stock  USD 0.50  0.00  0.00%   

Performance

7 of 100

 
Low
 
High
OK

Odds Of Distress

Less than 37

 
100  
 
Zero
Below Average
Epigenomics is trading at 0.5 as of the 28th of March 2024. This is a No Change since the beginning of the trading day. The stock's lowest day price was 0.5. Epigenomics has about a 37 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Epigenomics AG are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of February 2024 and ending today, the 28th of March 2024. Click here to learn more.
Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany. Epigenomics operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. The company has 4.09 M outstanding shares. More on Epigenomics AG
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

Epigenomics Pink Sheet Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Epigenomics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Epigenomics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
CEO BoardGregory Hamilton
Business ConcentrationDiagnostics & Research, Healthcare (View all Sectors)
Epigenomics AG [EPGNF] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC). The company currently falls under 'Nano-Cap' category with a current market capitalization of 6.01 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Epigenomics's market, we take the total number of its shares issued and multiply it by Epigenomics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Epigenomics AG classifies itself under Healthcare sector and is part of Diagnostics & Research industry. The entity has 4.09 M outstanding shares. Epigenomics AG has accumulated about 15.77 M in cash with (4.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.96, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Epigenomics Probability Of Bankruptcy
Ownership Allocation
Epigenomics AG retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months.
Check Epigenomics Ownership Details

Epigenomics Stock Price Odds Analysis

In reference to a normal probability distribution, the odds of Epigenomics jumping above the current price in 90 days from now is about 54.78%. The Epigenomics AG probability density function shows the probability of Epigenomics pink sheet to fall within a particular range of prices over 90 days. Assuming the 90 days horizon Epigenomics AG has a beta of -14.0137 suggesting as returns on its benchmark rise, returns on holding Epigenomics AG are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, Epigenomics is expected to outperform its benchmark. In addition to that, epigenomics AG has an alpha of 6.5799, implying that it can generate a 6.58 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
  Odds Below 0.5HorizonTargetOdds Above 0.5
45.16%90 days
 0.50 
54.78%
Based on a normal probability distribution, the odds of Epigenomics to move above the current price in 90 days from now is about 54.78 (This Epigenomics AG probability density function shows the probability of Epigenomics Pink Sheet to fall within a particular range of prices over 90 days) .

Epigenomics AG Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Epigenomics market risk premium is the additional return an investor will receive from holding Epigenomics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Epigenomics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Epigenomics' alpha and beta are two of the key measurements used to evaluate Epigenomics' performance over the market, the standard measures of volatility play an important role as well.

Epigenomics Stock Against Markets

Picking the right benchmark for Epigenomics pink sheet is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Epigenomics pink sheet price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Epigenomics is critical whether you are bullish or bearish towards Epigenomics AG at a given time. Please also check how Epigenomics' historical prices are related to one of the top price index indicators.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Epigenomics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Rebalancing Now

   

Portfolio Rebalancing

Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
All  Next Launch Module

Epigenomics Corporate Management

Elected by the shareholders, the Epigenomics' board of directors comprises two types of representatives: Epigenomics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Epigenomics. The board's role is to monitor Epigenomics' management team and ensure that shareholders' interests are well served. Epigenomics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Epigenomics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Antje ZeiseManager Investor RelationsProfile
Guenther ReiterMember of the Supervisory BoardProfile
Ann KesslerMember of the Supervisory BoardProfile
Jens RavensCFO BoardProfile
Helge LubenowMember of the Supervisory BoardProfile

How to buy Epigenomics Pink Sheet?

Before investing in Epigenomics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Epigenomics. To buy Epigenomics stock, you can follow these steps:
  • Choose a brokerage firm: You need to select a brokerage firm to buy shares of Epigenomics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
  • Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
  • Fund your account: You will need to deposit funds into your brokerage account to purchase Epigenomics stock. You can do this by transferring funds from your bank account or other investment accounts.
  • Place your order: Once you have located Epigenomics AG stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
  • Monitor your investment: After you have purchased Epigenomics AG stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Epigenomics AG, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments.

Already Invested in Epigenomics AG?

The danger of trading Epigenomics AG is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Epigenomics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Epigenomics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Epigenomics AG is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Epigenomics AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.

Complementary Tools for Epigenomics Pink Sheet analysis

When running Epigenomics' price analysis, check to measure Epigenomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Epigenomics is operating at the current time. Most of Epigenomics' value examination focuses on studying past and present price action to predict the probability of Epigenomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Epigenomics' price. Additionally, you may evaluate how the addition of Epigenomics to your portfolios can decrease your overall portfolio volatility.
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Please note, there is a significant difference between Epigenomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Epigenomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Epigenomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.